EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Infant Bacterial Therapeutics AB (publ) (IBT-B) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Infant Bacterial Therapeutics AB (publ) SEK 7.47, price SEK 69.50, upside -89.3%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SE · ISIN SE0008015259

IB Thin data Sep 24, 2026

Infant Bacterial Therapeutics AB (publ)

IBT-B · ST

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value kr 7.47 · Strongly overvalued (−89.3%)
!Quality 56/100
!Weak Growth (revenue YoY −94.8 %/yr)
!negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Infant Bacterial Therapeutics AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 124.50 kr 31.60 Fair Value kr 7.47 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 31.60 – kr 124.50 · fair‑value band kr 4.93 – kr 9.33 · the kr 69.50 price screens above the kr 7.47 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Infant Bacterial Therapeutics AB (publ) in your weekly email

Every Wednesday you see whether Infant Bacterial Therapeutics AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden.

Show more

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.

Stock analysis

Infant Bacterial Therapeutics AB (publ) (IBT-B) currently trades at kr 69.50, while our model-based Fair Value estimate is kr 7.47, 89.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 4.93 (bear) to kr 9.33 (bull), the price of kr 69.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Infant Bacterial Therapeutics AB (publ) reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −65.2M SEK in FY2025.

Key figures

Market cap 936M SEK (≈ $93.2M) · EPS (TTM) kr −5.30 · Return on equity −60.5% · Return on assets (EBIT) −33.8% · Revenue (TTM) −1.0K SEK · Revenue growth (YoY) −61.5% · EPS growth (YoY) −61.7% · Free cash flow −72.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 2% below its 52-week high and 60% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −89%, IBT-B screens richer than that median.

Fair Value models

Bear kr 4.93 Fair Value kr 7.47 Bull kr 9.33
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 4.05 kr 5.42 kr 8.09 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 4.05 kr 5.42 kr 8.09 51

Open the full fair value analysis →

Notify me when IBT-B reaches fair value

Put IBT-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 56/100

Of which business quality 59 · Market factors (momentum, volatility) 59

Profitability 0
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 59
Calm price path (market factor)
Momentum 57
Price trend over the last 3–12 months (market factor)
52W Momentum 63
Distance to the 52-week high (market factor)
Net Issuance 48
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−94.8%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15,185.3% (2017) → −3,497,550.0% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IBT-B screens overvalued: fair value 89% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Infant Bacterial Therapeutics AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 59 · Top 25%
Fair Value upside −89.3% · Bottom 25%
Profitability
Return on assets −26.7% · Below median
Operating margin (TTM) 0.0% · Above median
Growth and dividend
Revenue growth −61.5% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.89× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Infant Bacterial Therapeutics AB (publ) · Fair Value
kr 7.47 −89%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Infant Bacterial Therapeutics AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/IBT-B

Frequently asked questions

Is Infant Bacterial Therapeutics AB (publ) (IBT-B) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 7.47 versus a price of kr 69.50, about −89% upside (overvalued).
What is the fair value of IBT-B?
Our model-based fair value for Infant Bacterial Therapeutics AB (publ) is kr 7.47 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 69.50.
What is the quality score of IBT-B?
Infant Bacterial Therapeutics AB (publ) has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Our model-based price target is the fair value of kr 7.47 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 4.93, optimistic scenario kr 9.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Infant Bacterial Therapeutics AB (publ) stock forecast for 2026?
Our models put fair value at kr 7.47, about −89% upside versus a price of kr 69.50 (overvalued). Cautious scenario kr 4.93, optimistic scenario kr 9.33. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Infant Bacterial Therapeutics AB (publ) it is kr 7.47 per share (as of Sep 24, 2026), against a price of kr 69.50. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Infant Bacterial Therapeutics AB (publ) stock overvalued or undervalued in 2026?
As of Sep 24, 2026, IBT-B trades above its calculated fair value: price kr 69.50, fair value kr 7.47, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBT-B?
No. The price is what the market pays today (kr 69.50); the fair value is what the company's own numbers justify (kr 7.47). For Infant Bacterial Therapeutics AB (publ) the two are kr 62.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Infant Bacterial Therapeutics AB (publ) worth?
The market values Infant Bacterial Therapeutics AB (publ) at about 936M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 69.50; our models calculate a fair value of kr 7.47 per share.
What do the bullish and bearish scenarios say about IBT-B?
Our models span a range for Infant Bacterial Therapeutics AB (publ): cautious scenario kr 4.93, base kr 7.47, optimistic kr 9.33 per share (as of Sep 24, 2026, price kr 69.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Balance-sheet figures for Infant Bacterial Therapeutics AB (publ) (as of Sep 24, 2026): return on equity −60.5%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is IBT-B from its 52-week high?
Infant Bacterial Therapeutics AB (publ) trades at kr 69.50, about 2% below its 52-week high of kr 71.20 and 60% above the low of kr 43.45 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 7.47 is for.
Which stocks are comparable to Infant Bacterial Therapeutics AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Infant Bacterial Therapeutics AB (publ) stock attractive at the current price?
The data as of Sep 24, 2026: price kr 69.50, calculated fair value kr 7.47 (−89%), Quality Score 56/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IBT-B calculated?
We run Infant Bacterial Therapeutics AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 7.47, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Infant Bacterial Therapeutics AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
The closing price on Oct 2, 2026 was kr 69.50. Our model-based fair value is kr 7.47, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Infant Bacterial Therapeutics AB (publ) right now?
The price sits above even our optimistic bull case (kr 9.33). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 4.93 to kr 9.33) leaves room in how you read the outcome.

Key figures of Infant Bacterial Therapeutics AB (publ)

How large is the market capitalisation of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
The market capitalisation of Infant Bacterial Therapeutics AB (publ) is 936M SEK (≈ $93.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Earnings per share at Infant Bacterial Therapeutics AB (publ) are kr −5.30. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
The return on equity (ROE) of Infant Bacterial Therapeutics AB (publ) is −60.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
On an EBIT basis the return on assets of Infant Bacterial Therapeutics AB (publ) is −33.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much revenue does Infant Bacterial Therapeutics AB (publ) (IBT-B) generate?
Infant Bacterial Therapeutics AB (publ) generates revenue of −1.0K SEK (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Revenue at Infant Bacterial Therapeutics AB (publ) is growing −61.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Earnings per share at Infant Bacterial Therapeutics AB (publ) are growing −61.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Infant Bacterial Therapeutics AB (publ) (IBT-B) generate?
The free cash flow of Infant Bacterial Therapeutics AB (publ) is −72.3M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Infant Bacterial Therapeutics AB (publ) (IBT-B) hold?
Infant Bacterial Therapeutics AB (publ) holds more cash than debt, 144M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Infant Bacterial Therapeutics AB (publ) in the live analysis

One click puts Infant Bacterial Therapeutics AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.